16 completed, 8 unknown, 4 active not recruiting, 2 terminated. 12 Phase 4, 10 Phase 2, 3 Phase 1, 3 Phase 3, 2 Not applicable.
Follow Epclusa: new trials by email Literature Review of Epclusa trials Research Report on Epclusa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elimination of Hepatitis C Virus Among Users of Substances Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] - Hepatitis C in Substance Users | Not yet recruiting | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 1000 | 2027-03-15 | 2026-11-06 | |
| Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir - Hepatitis C, Cirrhosis | Phase 4 | Unknown | Peking University People's Hospital | 100 | 2022-09-01 | 2022-07-21 |
| Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet - Hepatitis C, Chronic, Pregnancy; Infection | Phase 4 | Active not recruiting | Catherine Anne Chappell | 100 | 2022-04-04 | 2026-10-19 |
| A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients Epclusa - End Stage Renal Disease | Phase 2 | Completed | University of Pennsylvania | 201 | 2021-06-22 | 2026-03-12 |
| Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir Sofosbuvir-Velpatasvir Drug Combination - Hepatitis C, Chronic | Phase 1 | Completed | Catherine Anne Chappell | 11 | 2020-10-22 | 2025-01-01 |
| A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams HCV RNA Point of Care, Sofosbuvir/velpatasvir, Glecaprevir/pibrentasvir - Hepatitis C | Not applicable | Completed | Kirby Institute | 101 | 2019-09-10 | 2023-01-17 |
| Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3) sofosbubir/velpatasvir, sofosbubir/velpatasvir/voxilaprevir - Hepatitis C, Chronic | Phase 4 | Unknown | Partners in Health | 100 | 2019-08-26 | 2019-09-11 |
| Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil Telemedicine, Velpatasvir/Sofosbuvir - Chronic Hepatitis C | Not applicable | Unknown | Hospital de Clinicas de Porto Alegre | 144 | 2019-08-23 | 2021-08-25 |
| The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients sofosbuvir/velpatasvir - Liver Transplant, Hepatitis C | Phase 2 | Completed | Fernanda P Silveira, MD, MS | 5 | 2019-08-15 | 2026-04-30 |
| HCV Post-Exposure Prophylaxis for Health Care Workers Sofosbuvir/Velpatasvir Treatment for 14 days - Hepatitis C | Phase 4 | Withdrawn | Massachusetts General Hospital | 2019-08-13 | 2020-01-21 | |
| Expanding the Pool in Lung Transplantation Epclusa - Hepatitis C, Lung Transplant | Phase 1 | Completed | Pablo Sanchez | 10 | 2019-07-30 | 2022-12-16 |
| The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients sofosbuvir/velpatasvir - Kidney Transplantation, Hepatitis C | Phase 2 | Active not recruiting | Amit D Tevar, MD | 30 | 2019-05-29 | 2025-11-06 |
| Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination Fingerstick GeneXpert HCV RNA quantitative assay, sofosbuvir/velpatesvir, glecaprevir/pibrentasvir - Hepatitis C, Hepatitis | Unknown | Kirby Institute | 600 | 2019-05-28 | 2022-04-14 | |
| Micro-elimination of Hepatitis C Virus Infection in Uremics Epclusa - Hepatitis C | Phase 3 | Unknown | Kaohsiung Medical University Chung-Ho Memorial Hospital | 135 | 2019-05-13 | 2020-07-10 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C | Phase 2 / Phase 3 | Completed | Ohio State University | 54 | 2019-03-22 | 2023-09-13 |
| Eliminating HCV Infection Among PWUD Epclusa - Hepatitis C, Chronic, Drug Use | Unknown | Vancouver Infectious Diseases Centre | 300 | 2019-02-22 | 2022-07-26 | |
| Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks - Respiratory Failure, Hepatitis C | Phase 4 | Terminated | Massachusetts General Hospital | 19 | 2019-02-05 | 2023-04-25 |
| Transplanting Hepatitis C Lungs Into Negative Lung Recipients Zepatier, Epclusa - Lung Diseases | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 10 | 2018-12-12 | 2023-04-14 |
| Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy - Hepatitis C, HIV-1-infection | Phase 4 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 400 | 2018-10-22 | 2022-02-04 |
| People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents Epclusa - Diabetes Mellitus, Hepatitis C, Chronic | Phase 4 | Active not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 121 | 2018-10-19 | 2026-10-22 |
Showing 20 of 33. Sign in to see all of them.
Hepatitis C (23) · Hepatitis C, Chronic (10) · Fibrosis (2) · Liver Diseases (2) · Lung Diseases (2) · Opioid-Related Disorders (2) · Acquired Immunodeficiency Syndrome (1) · Bone Diseases, Metabolic (1) · Carcinoma, Hepatocellular (1) · Cardiovascular Diseases (1) · Coinfection (1) · Cryoglobulinemia (1) · Diabetes Mellitus (1) · Digestive System Diseases (1) · Heart Failure (1)
Catherine Anne Chappell (2) · Kirby Institute (2) · Massachusetts General Hospital (2) · University of Pennsylvania (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Ala'a Sharara (1) · Amit D Tevar, MD (1) · Baylor Research Institute (1) · Brigham and Women's Hospital (1) · Cocrystal Pharma, Inc. (1) · Duke University (1) · Elizabeth Krans, MD (1) · Fernanda P Silveira, MD, MS (1) · Fondazione Italiana Linfomi - ETS (1) · Hospital de Clinicas de Porto Alegre (1)
United States (20) · Canada (4) · Australia (2) · Brazil (2) · Taiwan (2) · Italy (1) · Lebanon (1) · Puerto Rico (1) · Rwanda (1) · South Africa (1) · Thailand (1) · Uganda (1)
Catherine Chappell, MD, MSc (2) · Fernanda Silviera, MD (2) · Alexander Wong, MD (1) · Amit Tevar, MD (1) · Elizabeth E Krans, MD, MSc (1) · Fredrick Kateera, MD, PhD (1) · Graciela Castro-Narro, MD (1) · Huiying Rao, Dr. (1) · Jia-Horng Kao, PhD (1) · Joel Chua, MD (1) · John Cafardi, MD (1) · Lindsey Baden, MD (1) · Luca Arcaini (1) · Marc G Ghany, M.D. (1) · Marcelo Cypel, MD MSc FRCSC (1)
PMID 30552056, PMID 30946553, PMID 31606437, PMID 31790766, PMID 33303567, PMID 34596223, PMID 35026142, PMID 35248212, PMID 35248213, PMID 35714311, PMID 36694361, PMID 36863287, PMID 38046041, PMID 39702964, PMID 40019678, PMID 40273497, PMID 41250046, PMID 41255102
R21HD101996 (1), U01DK126654 (1), UM1AI068636 (1)